一项评估艾司氯胺酮减轻重度抑郁症症状疗效和安全性的研究 (AVENUE)
一项双盲、随机、活性安慰剂对照研究,评估鼻内给予84毫克艾氯胺酮联合综合标准治疗在具有急性自杀意念或行为的青少年参与者中快速减轻重度抑郁症症状的有效性和安全性
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
学习地点
-
-
-
Budapest、匈牙利、1021
- 招聘中
- Vadaskert Gyermek es Ifjusagpszichiatriai Korhaz es Szakambulancia
-
Debrecen、匈牙利、4031
- 招聘中
- Debreceni Egyetem Klinikai Kozpont
-
Győr、匈牙利、9023
- 招聘中
- Petz Aladar Megyei Oktato Korhaz
-
Szeged、匈牙利、6720
- 招聘中
- Szegedi Tudomanyegyetem
-
-
-
-
-
New Taipei City、台湾、251
- 招聘中
- Mackay Memorial Hospital Tamsui Branch
-
Taipei、台湾、114
- 招聘中
- Tri-Service General Hospital
-
Taipei、台湾、100
- 招聘中
- National Taiwan University Hospital
-
Taipei、台湾、112
- 招聘中
- Taipei Veterans General Hospital
-
Taipei、台湾、110
- 招聘中
- Taipei Medical University Hospital
-
-
-
-
-
Criciúma、巴西、88811 000
- 招聘中
- Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose
-
Natal、巴西、59012 300
- 招聘中
- Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes
-
Salvador、巴西、40170 108
- 招聘中
- Instituto Apice
-
São Bernardo do Campo、巴西、09726 150
- 招聘中
- Centro Integrado Facili
-
São Paulo、巴西、01 227 200
- 招聘中
- Instituto de Pesquisa Pensi Sandra Mutarelli Setubal
-
São Paulo、巴西、05403-900
- 招聘中
- Hospital Das Clinicas Da Faculdade De Medicina Da USP
-
-
-
-
-
Acireale、意大利、95024
- 招聘中
- Presidio Ospedaliero Santa Marta e Santa Venera
-
Cagliari、意大利、09134
- 招聘中
- Azienda Ospedaliera G. Brotzu
-
Florence、意大利、50134
- 招聘中
- AOU Meyer
-
Foggia、意大利、71122
- 招聘中
- Azienda Ospedaliera Universitaria Policlinico Riuniti di Foggia
-
Genova、意大利、16147
- 招聘中
- G.Gaslini Institute
-
Merano、意大利、39012
- 招聘中
- Ospedale di Merano
-
Naples、意大利、80131
- 招聘中
- Azienda Ospedaliera Universitaria Federico II
-
Sassari、意大利、07100
- 招聘中
- Azienda Ospedaliero Universitaria di Sassari
-
-
-
-
-
Bucharest、罗马尼亚、041914
- 招聘中
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
-
Cluj-Napoca、罗马尼亚、400347
- 招聘中
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Sibiu、罗马尼亚、550082
- 招聘中
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
-
Timișoara、罗马尼亚、300329
- 招聘中
- Spitalul Clinic de Urgenta pentru Copii 'Louis Turcanu' Timisoara
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 招聘中
- University of Alabama at Birmingham
-
-
Connecticut
-
New Haven、Connecticut、美国、06511
- 招聘中
- Yale Child Study Center
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 招聘中
- Children's National Medical Center
-
-
Georgia
-
Atlanta、Georgia、美国、30338
- 招聘中
- Peachford Hospital-Atlanta Behavioral Research
-
-
Illinois
-
Evanston、Illinois、美国、60201
- 招聘中
- Endeavor Health Evanston Hospital
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins University
-
-
Massachusetts
-
Boston、Massachusetts、美国、02445
- 招聘中
- Boston Childrens Hospital
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27514
- 招聘中
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- 招聘中
- University of Cincinnati
-
-
Rhode Island
-
East Providence、Rhode Island、美国、02915
- 招聘中
- Bradley Hospital
-
-
Texas
-
Houston、Texas、美国、77021
- 招聘中
- John S Dunn Behavioral Sciences Center at UTHealth Houston
-
-
-
-
-
Barcelona、西班牙、08036
- 招聘中
- Hosp. Clinic de Barcelona
-
Barcelona、西班牙、08035
- 招聘中
- Hosp Univ Vall D Hebron
-
Esplugues de Llobregat、西班牙、08950
- 招聘中
- Hosp. Sant Joan de Deu
-
Madrid、西班牙、28046
- 招聘中
- Hosp. Univ. La Paz
-
Madrid、西班牙、28009
- 招聘中
- Hosp. Gral. Univ. Gregorio Maranon
-
Manresa、西班牙、08243
- 招聘中
- Fundacio Althaia Xarxa Assistencial Universitaria de Manresa
-
Oviedo、西班牙、33011
- 招聘中
- Hosp. Univ. Central de Asturias
-
Pamplona、西班牙、31008
- 招聘中
- Clinica Univ. de Navarra
-
Sabadell、西班牙、08208
- 招聘中
- Hosp.Univ.Parc Tauli
-
Santander、西班牙、39008
- 招聘中
- Hosp. Univ. Marques de Valdecilla
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Must meet diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for major depressive disorder (MDD) based upon clinical assessment and confirmed by the mini-international neuropsychiatric interview for children and adolescents (MINI-KID)
- Must have a clinical global impression - severity of suicidality - revised (CGI-SS-R) score of "Markedly" or greater (that is, greater than or equal to [>=] 4) at both screening and baseline (predose) visits
- Must have a children's depression rating scale - revised (CDRS-R) total score >= 58 at baseline (predose)
- In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to subject's acute suicidality
- Must be medically stable based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
Exclusion Criteria:
- Participant has a current DSM-5 diagnosis of bipolar (or related disorders), intellectual disability, autism spectrum disorder, conduct disorder, oppositional defiant disorder
- Participant currently meets DSM-5 criteria for borderline personality disorder
- Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychosis
- Participant has a history of seizure disorder
- Participant has known allergies, hypersensitivity, intolerance or contraindications to midazolam, esketamine or ketamine, or their excipients
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intranasal Esketamine + Oral Placebo
Participants will receive intranasal esketamine 84 milligrams (mg) along with oral placebo solution twice weekly for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25). On Day 4 a decrease to intranasal esketamine 56 mg (in a blinded fashion per investigator's judgment) is permitted. Thereafter, dose may be flexed between 56 mg and 84 mg during the treatment period. |
Esketamine will be administered as intranasal solution.
其他名称:
Placebo will be administered as oral solution. |
|
安慰剂比较:Intranasal Placebo + Oral Midazolam
Participants will receive oral midazolam (0.0625 milligrams per kilograms [mg/kg]) and intranasal placebo twice weekly for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25). On Day 4 a sham decrease to esketamine 56 mg dose (in a blinded fashion per investigator's judgment) is permitted. Thereafter, sham dose may be flexed between 56 mg and 84 mg during the treatment period. |
Midazolam will be administered as oral solution. Intranasal placebo will be administered as nasal solution. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Depressive Symptoms Measured by Children's Depression Rating Scale - Revised (CDRS-R) Total Score at 24 Hours Post First Dose
大体时间:Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5 point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome. |
Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in CDRS-R Total Score at Day 25
大体时间:Baseline (predose on Day 1) and Day 25 (4 hours post dose)
|
The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome. |
Baseline (predose on Day 1) and Day 25 (4 hours post dose)
|
|
Change from Baseline in Clinical Global Impression - Severity of Suicidality - Revised (CGI-SS-R) Score at 24 Hours Post First Dose
大体时间:Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
The CGI-SS-R is a single item clinician-rated measure of the severity of participants' suicidality. The CGI-SS-R asks clinicians to rate the severity of a participant's suicidality using a 7-point scale that ranges from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients). Higher scores indicate greater severity. |
Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
|
Change From Baseline in Symptoms of MDD During the Double-Blind (DB) Treatment Phase as Measured by CDRS-R Total Score
大体时间:From Baseline up to Day 25
|
The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome. |
From Baseline up to Day 25
|
|
Percentage of Participants with Remission of Depressive Symptoms During the DB Treatment Phase
大体时间:Up to Day 25
|
Remission of depressive symptoms is defined as a CDRS-R total score of both less than or equal to (<=) 28 and <= 34 during the DB treatment phase. The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5 point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome. |
Up to Day 25
|
|
Percentage of Responders on Depressive Symptoms During the DB Treatment Phase
大体时间:Up to Day 25
|
Responders on depressive symptoms is defined as >= 50 percent (%) improvement in CDRS-R total score from baseline during the DB treatment phase. The CDRS-R is a 17-item, clinician-reported outcome measure of children's depressive symptom severity. Out of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5 point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome. |
Up to Day 25
|
|
Percentage of Participants with Resolution of Suicidality During the DB Treatment Phase
大体时间:Up to Day 25
|
Participants with resolution of suicidality is defined as a score of 0 (normal, not at all suicidal) or 1 (questionably suicidal) on CGI SS-R, during the DB treatment phase. The CGI-SS-R asks clinicians to rate the severity of a participant's suicidality using a 7-point scale that ranges from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients). Higher score indicate greater severity. |
Up to Day 25
|
|
Change From Baseline in Severity of Suicidality As Measured by Clinical Global Impression - Severity of Suicidality - Revised (CGI-SS-R) During the DB Treatment Phase
大体时间:From Baseline up to Day 25
|
The CGI-SS-R is a single item clinician-rated measure of the severity of participants' suicidality. The CGI-SS-R asks clinicians to rate the severity of a participant's suicidality using a 7-point scale that ranges from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal patients). Higher score indicate greater severity. |
From Baseline up to Day 25
|
|
Change From Baseline in Clinician-Reported Frequency of Suicidal Thinking (FoST-ClinRO) During the DB Treatment Phase
大体时间:From Baseline up to Day 25
|
FoST-ClinRO is a clinician-rated measure used to assess a participant's frequency of suicidal thinking assessed during the DB treatment phase. The measure uses a 6-point Likert scale that ranges from 0=Never, to 5=All of the time to assess suicidal thinking frequency, where higher scores indicate a more severe condition. |
From Baseline up to Day 25
|
|
Change from baseline in Patient-Reported Frequency of Suicidal Thinking (FoST-PRO) During the DB Treatment Phase
大体时间:From Baseline up to Day 25
|
FoST-PRO is a single item participant reported measure of the frequency of one's suicidal thinking right now. The single item asks participants to rate the frequency with which they have suicidal thoughts (0 = I have no suicidal thoughts, 1 = I have suicidal thoughts a little of the time, 2 = I have suicidal thoughts some of the time, 3 = I have suicidal thoughts most of the time, and 4 = I have suicidal thoughts all of the time). Higher scores indicate greater severity. |
From Baseline up to Day 25
|
|
Change from Baseline in Patient Health Questionnaire, 9-item Modified for Adolescents (PHQ-A) Total Score During the DB Treatment Phase
大体时间:From Baseline up to Day 25
|
The PHQ-A is a modified version of the PHQ-9 scale, specifically designed to measure depressive symptom severity in adolescents. A 10-item version of the PHQ-A will be used in this study; the first 9 items assess depressive symptoms. Adolescents use a 4 point Likert scale to rate the severity of their symptoms over the past 2 weeks (range: 0 = not at all to 3 = nearly every day). The PHQ-A total score is the sum of all item responses. The total score can be used to classify adolescents based on the severity of their depressive symptoms: 0-4 (no or minimal depression), 5-9 (mild depression), 10-14 (moderate depression), 15-19 (moderately severe depression), and 20-27 (severe depression). The tenth PHQ-A item measures the degree to which adolescents experience functional difficulties due to their depressive symptoms. Higher scores indicate greater depressive symptoms. |
From Baseline up to Day 25
|
|
Change From Baseline in KIDSCREEN-10 Total Score During the DB Treatment Phase
大体时间:From Baseline up to Day 25
|
KIDSCREEN-10 is a global patient-reported outcome (PRO) measure of well-being and health-related quality of life in children and adolescents aged 8-18 years. It includes 10 items that measure the subjective health and psychological, mental and social well-being experiences of children and adolescents over the past week. The scores for the 10 items are summed to produce a total score. This total score can then be transformed into a T-score or percentile rank, based on normative data, to facilitate interpretation. The higher the total score, the better the reported health-related quality of life (HRQoL). |
From Baseline up to Day 25
|
|
Change from Baseline in Patient Global Impression of Severity (PGI-S) Depressive Symptoms at 24 Hours Post First Dose
大体时间:Baseline (predose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
The PGI-S is a single PRO item that captures one's perceptions of the severity of his/her depressive symptoms over the past 24 hours. Participants will be asked to rate their disease severity using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe. Higher scores indicate greater disease severity. |
Baseline (predose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
|
Change from Baseline in Clinical Global Impression - Severity Scale (CGI-S) Depressive Symptoms at 24 Hours Post First Dose
大体时间:Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that considers all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S will be used to rate the overall severity of illness on a scale of 1 to 7. Considering total clinical experience with the depression population, a participant is assessed on severity of illness at the time of rating according to the following scale: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Higher scores indicate greater severity. |
Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 54135419SUI3003
- 54135419SUI3003 (其他标识符:Janssen Research & Development, LLC)
- 2024-518615-19-00 (注册表标识符:EUCT number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.